Generex/Antigen Express Interview on Clear Channel Business Talk Radio DFW 1190AM by Host Michael Yorba

Generex/Antigen Express Interview on Clear Channel Business Talk Radio DFW 
1190AM by Host Michael Yorba 
Interview Today, Wed, Feb 12, at 2:15 pm EST 
WORCESTER, MA and TORONTO, ON -- (Marketwired) -- 02/12/14 -- 
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT)
today announced that Dr. Eric von Hofe, PhD, President of the
Company's wholly-owned subsidiary, Antigen Express, Inc.
(www.antigenexpress.com), will be interviewed live today on Clear
Channel's business talk radio show "The Traders Network" by host
Michael Yorba: 
Live iHeart Radio Stream:
http://www.iheart.com/live/4276/?autoplay=true 
 Date: Wednesday,
February 12, 2014
 Time: 2:15 pm EST (1:15 CST, 11:15 PST)
 Network:
Clear Channel
 Show: The Traders Network
 Station: DFW 1190AM
 Host:
Michael Yorba 
The interview will canvass the increasing importance of
immunotherapies in the treatment of cancers, and the proprietary
Antigen Express vaccine technology, presently in a late Phase II
trial in breast cancer patients. 
About Clear Channel
 Clear Channel Media and Entertainment's more
than 840 radio stations offer programming nationwide. Individual
station brands connect with diverse audiences in local markets across
the country reaching more than 112 million listeners.
www.clearchannel.com. 
About Michael Yorba 
 Mr. Yorba is the founder of Yorba Media and
featured host on Clear Channel's DFW 1190AM in Dallas-Ft. Worth, TX.
For the past six years he has been integrally involved with producing
and hosting a daily talk show called Commodity Classics, and The
Traders Network.  
From the fast action of the trading pit... to the power brokers
making the headlines... Michael Yorba interviews the front-page
Titans about the latest in capital markets, CEO milestones, trading
tools and market trends. Learn how the experts use risk management
techniques to build fully diversified portfolios and what it takes to
put up big board earnings. It's a fast moving, high-energy show that
presents stocks, commodities, bonds, forex, derivatives, political
trends, crowd funding and impact investment insights in a new light
and keeps investors and consumers asking for more... The Traders
Network stays ahead of the curve by featuring leading market and
business professionals, sophisticated technology, and the analytics
needed to identify the most lucrative investment strategies.
Successful performance depends on finding the right opportunities.
So... shift your thinking and join us as we deliver "tomorrow's ideas
today" on Clear Channel's The Traders Network Monday - Friday from
1:00pm - 3:00pm CST live after Glenn Beck.  
About Generex Biotechnology Corporation
 Generex is engaged in the
research, development, and commercialization of drug delivery systems
and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the
oral cavity (with no deposit in the lungs). The Company's proprietary
liquid formulations allow drugs typically administered by injection
to be absorbed into the body by the lining of the inner mouth using
the Company's proprietary RapidMist(TM) device. Antigen Express, Inc.
is a wholly owned subsidiary of Generex. The core platform
technologies of Antigen Express comprise immunotherapeutic vaccines
for the treatment of malignant, infectious, allergic, and autoimmune
diseases. Antigen Express has pioneered the use of specific CD4+
T-helper stimulation technologies in immunotherapy. One focuses on
modification of peptides with Ii-Key to increase potency, while a
second relies on inhibition of expression of the Ii protein. Antigen
Express scientists, and others, have shown clearly that suppression
of expression of the Ii protein in cancer cells allows for potent
stimulation of T-helper cells and prevents the further growth of
cancer cells. For more information, visit the Generex website at
www.generex.com or the Antigen Express website at
www.antigenexpress.com. 
Cautionary Note Regarding Forward-Looking Statements
 This release
and oral statements made from time to time by Generex representatives
in respect of the same subject matter may contain "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements can be identified by
introductory words such as "expects," "plan," "believes," "will,"
"achieve," "anticipate," "would," "should," "subject to" or words of
similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Forward-looking statements frequently
are used in discussing potential product applications, potential
collaborations, product development activities, clinical studies,
regulatory submissions and approvals, and similar operating matters.
Many factors may cause actual results to differ from forward-looking
statements, including inaccurate assumptions and a broad variety of
risks and uncertainties, some of which are known and others of which
are not. Known risks and uncertainties include those identified from
time to time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise. Generex cannot
be sure when or if it will be permitted by regulatory agencies to
undertake additional clinical trials or to commence any particular
phase of clinical trials. Because of this, statements regarding the
expected timing of clinical trials or ultimate regulatory approval
cannot be regarded as actual predictions of when Generex will obtain
regulatory approval for any "phase" of clinical trials or when it
will obtain ultimate regulatory approval by a particular regulatory
agency. Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private
Securities Litigation Reform Act. 
A www.1800PublicRelations.com PR Event  
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2518064 
Generex Contact:
Generex Biotechnology Corporation
Todd Falls
800-391-6755 
Press/Media Contact:
Matthew Bird
President 
MUNCmedia Public Relations
+1 (917) 409-8211
matt.bird@muncmedia.com
www.muncmedia.com 
 
 
Press spacebar to pause and continue. Press esc to stop.